These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12099580)

  • 1. New trial designs to assess antitumor and antiproliferative agents in prostate cancer.
    Stadler W
    Invest New Drugs; 2002 May; 20(2):201-8. PubMed ID: 12099580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of target-based antineoplastic agents.
    Stadler WM; Ratain MJ
    Invest New Drugs; 2000 Feb; 18(1):7-16. PubMed ID: 10830137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
    Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
    Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial designs for multiple myeloma.
    Hoering A; Crowley J
    Clin Adv Hematol Oncol; 2007 Apr; 5(4):309-16. PubMed ID: 17607290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.
    Lieberman R
    Urology; 2001 Apr; 57(4 Suppl 1):224-9. PubMed ID: 11295633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The design of clinical trials for new molecularly targeted compounds: progress and new initiatives.
    Seymour L
    Curr Pharm Des; 2002; 8(25):2279-84. PubMed ID: 12369856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel strategies to test biological hypotheses in early drug development for advanced prostate cancer.
    Ferraldeschi R; Attard G; de Bono JS
    Clin Chem; 2013 Jan; 59(1):75-84. PubMed ID: 23204221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials.
    Priolo C; Oh WK; Loda M
    IDrugs; 2009 Mar; 12(3):165-8. PubMed ID: 19333896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial methods to discover and validate predictive markers for treatment response in cancer.
    Paik S
    Biotechnol Annu Rev; 2003; 9():259-67. PubMed ID: 14650930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The phase II/III transition. Toward the proof of efficacy in cancer clinical trials.
    Fazzari M; Heller G; Scher HI
    Control Clin Trials; 2000 Aug; 21(4):360-8. PubMed ID: 10913810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug development in prostate cancer.
    Ripple GH; Wilding G
    Semin Oncol; 1999 Apr; 26(2):217-26. PubMed ID: 10597732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. End points in cancer clinical trials and the drug approval process.
    Schilsky RL
    Clin Cancer Res; 2002 Apr; 8(4):935-8. PubMed ID: 11948095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity.
    Miglietta L; Cannobbio L; Boccardo F
    Anticancer Res; 1995; 15(6B):2825-8. PubMed ID: 8669872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular-targeted therapy for prostate cancer].
    Miyake H; Fujisawa M
    Nihon Rinsho; 2016 Jan; 74(1):2-5. PubMed ID: 26793871
    [No Abstract]   [Full Text] [Related]  

  • 15. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.
    Small EJ; McMillan A; Meyer M; Chen L; Slichenmyer WJ; Lenehan PF; Eisenberger M
    J Clin Oncol; 2001 Mar; 19(5):1304-11. PubMed ID: 11230472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design considerations for efficient prostate cancer chemoprevention trials.
    Lee JJ; Lieberman R; Sloan JA; Piantadosi S; Lippman SM
    Urology; 2001 Apr; 57(4 Suppl 1):205-12. PubMed ID: 11295629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy.
    Sridhara R; Eisenberger MA; Sinibaldi VJ; Reyno LM; Egorin MJ
    J Clin Oncol; 1995 Dec; 13(12):2944-53. PubMed ID: 8523059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials.
    Collette L; Burzykowski T; Schröder FH
    Eur J Cancer; 2006 Jul; 42(10):1344-50. PubMed ID: 16730974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Phase Clinical Trial Designs - State of Play and Adapting for the Future.
    Harrington JA; Hernandez-Guerrero TC; Basu B
    Clin Oncol (R Coll Radiol); 2017 Dec; 29(12):770-777. PubMed ID: 29108786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The study landscape for prostate cancer].
    Miller K
    Urologe A; 2005 Dec; 44(12):1431-4. PubMed ID: 16292461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.